Eli Lilly’s Tirzepatide Reduces Heart Failure Risks, Study Reveals

Revolutionary Heart Failure Treatment

Eli Lilly’s drug tirzepatide, marketed as Mounjaro for diabetes and Zepbound for weight loss, has shown promising results in improving symptoms in heart failure patients with obesity, the company announced Thursday. This adds to the growing evidence that GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, offer benefits beyond diabetes and weight loss.

In Lilly’s latest trial, patients treated with tirzepatide were 38% less likely to be hospitalized, require increased heart failure medication, or die from heart complications compared to those who received a placebo. Additionally, patients reported reduced shortness of breath, fatigue, and lower leg swelling over the 52-week trial period. However, these findings, released in a news release, have yet to be published in a medical journal or reviewed by external scientists.

Heart failure affects 6.7 million U.S. adults and caused nearly 14% of deaths in 2022. Dr. Anu Lala from Mount Sinai Fuster Heart Hospital highlights the revolutionary impact of new drugs on symptoms, functional capacity, and quality of life. She is already using these medications in her practice.

The Lilly study focused on patients with heart failure with preserved ejection fraction, a condition affecting up to half of heart failure patients. This condition involves the stiffening of heart walls, making it difficult for the heart to fill with and pump blood effectively. Approximately 60% of these patients also have obesity, according to Dr. Jeff Emmick, senior vice president of product development at Lilly.

While the exact mechanism behind the drug’s effectiveness remains unclear, Dr. Emmick hypothesized that it might be related to a reduction in fat around the heart.

In April, Lilly reported tirzepatide reduces sleep apnea in obese adults. The FDA also expanded Wegovy’s approval to lower heart disease risk, and semaglutide (in Wegovy and Ozempic) was found to reduce kidney disease complications.

As Elon Musk once said, “When something is important enough, you do it even if the odds are not in your favor.” This breakthrough in heart failure treatment exemplifies the potential for innovative therapies to transform patient care.